CytomX Therapeutics Inc (CTMX)
0.89
+0.02
(+2.71%)
USD |
NASDAQ |
Nov 22, 16:00
0.8913
0.00 (0.00%)
After-Hours: 20:00
CytomX Therapeutics Total Liabilities (Quarterly): 162.43M for Sept. 30, 2024
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 162.43M |
| June 30, 2024 | 190.45M |
| March 31, 2024 | 216.37M |
| December 31, 2023 | 249.24M |
| September 30, 2023 | 272.40M |
| June 30, 2023 | 294.21M |
| March 31, 2023 | 321.27M |
| December 31, 2022 | 346.64M |
| September 30, 2022 | 198.02M |
| June 30, 2022 | 211.38M |
| March 31, 2022 | 228.63M |
| December 31, 2021 | 339.87M |
| September 30, 2021 | 259.56M |
| June 30, 2021 | 271.49M |
| March 31, 2021 | 288.14M |
| December 31, 2020 | 366.44M |
| September 30, 2020 | 327.12M |
| June 30, 2020 | 343.65M |
| March 31, 2020 | 366.90M |
| December 31, 2019 | 290.17M |
| Date | Value |
|---|---|
| September 30, 2019 | 290.44M |
| June 30, 2019 | 303.78M |
| March 31, 2019 | 321.94M |
| December 31, 2018 | 326.22M |
| September 30, 2018 | 325.06M |
| June 30, 2018 | 335.81M |
| March 31, 2018 | 326.82M |
| December 31, 2017 | 327.75M |
| September 30, 2017 | 341.56M |
| June 30, 2017 | 299.62M |
| March 31, 2017 | 104.10M |
| December 31, 2016 | 120.65M |
| September 30, 2016 | 103.46M |
| June 30, 2016 | 105.67M |
| March 31, 2016 | 79.24M |
| December 31, 2015 | 71.15M |
| September 30, 2015 | 230.83M |
| June 30, 2015 | 70.49M |
| December 31, 2014 | 151.60M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
162.43M
Minimum
Sep 2024
366.90M
Maximum
Mar 2020
277.22M
Average
280.27M
Median
Total Liabilities (Quarterly) Benchmarks
| Spero Therapeutics Inc | 69.65M |
| NovaBay Pharmaceuticals Inc | 2.805M |
| Palatin Technologies Inc | 11.10M |
| iBio Inc | 6.763M |
| Theriva Biologics Inc | 15.47M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 138.98M |
| Shareholders Equity (Quarterly) | -23.45M |
| Current Ratio | 1.042 |